Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone) May 5, 2020 09:14AM
Regeneron Reports Third Quarter 2016 Financial and Operating Results Nov 4, 2016 06:30AM
Janssen to Present Data Across Broad Rheumatology Portfolio and Immunology Pipeline at the 2016 American College of Rheumatology Meeting Nov 3, 2016 08:00AM
Teva Pharma (TEVA), Regeneron (REGN) Announce FDA Clinical Hold Placed on Fasinumab Phase 2b Oct 17, 2016 07:05AM
Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs Oct 17, 2016 07:00AM


Oct 17, 2016 07:00AM Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
Sep 20, 2016 07:03AM Regeneron (REGN), Teva Pharma (TEVA) Enter Partnership for Fasinumab Development, Commercialization
Sep 20, 2016 07:00AM Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Sep 20, 2016 07:00AM Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
Sep 9, 2016 06:06AM Janssen to Make Several INVOKANA Presentations at EASD Annual Meeting
Sep 9, 2016 02:30AM Janssen to Present Data from Nine Abstracts on INVOKANA® (canagliflozin) at 2016 European Association for the Study of Diabetes Annual Meeting
Sep 9, 2016 02:30AM Janssen to Present Data from Nine Abstracts on INVOKANA® (canagliflozin) at 2016 European Association for the Study of Diabetes Annual Meeting
Jun 13, 2016 09:15AM Canagliflozin Phase 2 Study Demonstrates Glycemic Improvements in Adults With Type 1 Diabetes
Jun 11, 2016 11:00AM New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management
May 16, 2016 08:00AM Janssen To Present New Inflammatory Bowel Disease Data At Digestive Disease Week Meeting
May 2, 2016 07:02AM Regeneron (REGN) Announces Statistically Significant Data from Fasinumab Phase 2/3
May 2, 2016 07:00AM Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Apr 21, 2016 07:15AM Biogen Reports First Quarter 2016 Revenues of $2.7 Billion
Nov 4, 2015 08:21AM Janssen Data Presentations At American College of Rheumatology Meeting Showcase Commitment To Rheumatologic Diseases
Nov 4, 2015 06:30AM Regeneron Reports Third Quarter 2015 Financial and Operating Results
Oct 1, 2015 04:05PM Regeneron Announces Collaboration with Mitsubishi Tanabe Pharma for Investigational Pain Therapy Fasinumab in Asia
Sep 16, 2015 09:00AM Amgen To Acquire Privately-Held Dezima Pharma
Jun 26, 2015 04:42AM SIMPONI® Receives European Commission Approval for Treatment of Non-radiographic Axial Spondyloarthritis
Jun 2, 2015 02:00AM Data at EULAR 2015 Showcase Commitment of Janssen to Advancing Innovative Treatments for Immune and Inflammatory Diseases
May 26, 2015 06:33AM SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
Apr 28, 2015 08:00AM Janssen Launches U.S. Hispanic Community Initiative to Help Improve Type 2 Diabetes Care